Who are Pemetrexed plus Pembrolizumab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pemetrexed-plus-pembrolizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Pemetrexed plus Pembrolizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pemetrexed plus Pembrolizumab (Pemetrexed plus Pembrolizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifolate antimetabolite + PD-1 inhibitor combination. Area: Oncology.

phase 3 Antifolate antimetabolite + PD-1 inhibitor combination Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase (pemetrexed); PD-1 (pembrolizumab) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Pemetrexed plus Pembrolizumab (Pemetrexed plus Pembrolizumab) — Hunan Province Tumor Hospital. Pemetrexed inhibits folate-dependent enzymes to disrupt cancer cell DNA synthesis, while pembrolizumab blocks PD-1 to unleash immune attack against tumor cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pemetrexed plus Pembrolizumab TARGET	Pemetrexed plus Pembrolizumab	Hunan Province Tumor Hospital	phase 3	Antifolate antimetabolite + PD-1 inhibitor combination	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase (pemetrexed); PD-1 (pembrolizumab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifolate antimetabolite + PD-1 inhibitor combination class)

Hunan Province Tumor Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pemetrexed plus Pembrolizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/pemetrexed-plus-pembrolizumab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab